- All categories
- Biological Sciences
- Medicine, Human Health
- Biostatistics, Epidemiology
- Clinical Research, Trials
- Cytology, Cancerology, Oncology
- Dentristry / Odontology, Stomatology Technology
- Diagnostics, Diagnosis
- Environmental Medicine, Social Medicine, Sports Medicine
- Gene - DNA Therapy
- Gerontology and Geriatrics
- Heart and blood circulation illnesses
- Medical Research
- Medical Technology / Biomedical Engineering
- Neurology, Brain Research
- Pharmaceutical Products / Drugs
- Physiology
- Surgery
- Virus, Virology / Antibiotics / Bacteriology
- Physiotherapy, Orthopaedic Technology
- Single Use Products and Consumer Goods
- Medical Textiles
- Medical Furniture
- Medical Biomaterials
- Stem cell Technologies
- Human vaccines
- Emergency Medicine Technology
- Communications
- Computer related
- Electronics Related Market
- Genetic Engineering / Molecular Biology
- Medical Health related
- Energy Market
- Consumer related
- Industrial Products
- Other
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
New use for an existing drug as antiviral agent against SARS-CoV-2 to prevent or/and treat COVID-19CSIC has discovered a new use for an existing drug on the market as antiviral agent. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.
Marta García Del BarrioConsejo Superior de Investigaciones Cientificas (CSIC)Marta García Del Barrio
Commercialization Specialist at Consejo Superior de Investigaciones Cientificas (CSIC)
View ProfileMarta García Del Barrio posted this:
Commercialization Specialist at Consejo Superior de Investigaciones Cientificas (CSIC)
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
SARS-CoV-2 Targeted Libraries for offerProtease-Oriented SARS-CoV-2 Library (1017 Compounds) - Developed by Virtual Receptor-Based Screening Using the Crystal Structure of the Basic SARS-CoV-2 Protease (PDB ID: 6LU7) ML (Machine Learning) SARS-target library (1577 compounds) - carefully developed using machine learning (artificial neural networks and Bayesian statistics).
Nadiia KachaputOtava Research InstituteNadiia Kachaput posted this:
Project coordinator at Otava Research Institute
Nadiia KachaputOtava Research InstituteNadiia Kachaput posted this:
Project coordinator at Otava Research Institute
Nadiia KachaputOtava Research InstituteNadiia Kachaput posted this:
Project coordinator at Otava Research Institute
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget
Nadiia KachaputOtava Research InstituteNadiia Kachaput posted this:
Project coordinator at Otava Research Institute
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
SARS-CoV-2 Papain-like ProteaseTargeted LibraryUsing receptor based virtual screening OtavaResearchInstitute’s team designed the SARS-CoV-2 Papain-like Protease PLpro Targeted Library, which is contain 1058 stock compounds with predicted activity against this protease and ready for delivery.
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
SARS-CoV-2 NSP16 Targeted LibrarySARS-CoV-2 2′-O-methyltransferase (NSP16) Targeted Library, which contains 1049 compounds with predicted activity against SARS-CoV-2 NSP16 is offered. The library has been designed with receptor-based virtual screening using crystal structure of SARS-CoV-2 2′-O-MTase (PDB ID: 6WKQ).
Nadiia KachaputOtava Research InstituteNadiia Kachaput posted this:
Project coordinator at Otava Research Institute
Nadiia KachaputOtava Research InstituteNadiia Kachaput posted this:
Project coordinator at Otava Research Institute
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
SARS-CoV-2 Helicase Targeted LibraryThe offer SARS-CoV-2 Helicase (NSP13) Targeted Library, which contain 1170 compounds with predicted activity against this vital protein. The overall procedure included accurate flexible docking of Drug-like Green Collection into helicase active site.
Nadiia KachaputOtava Research InstituteNadiia Kachaput posted this:
Project coordinator at Otava Research Institute
Covid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by InnogetCovid-19 Innovation Challenges by Innoget posted this:
Shimmer3 Bioimpedance Monitor - Monitoring HR, respiration rate and depth, and the increase in fluid in the lungs to triage and remotely monitor Covid-19 patientsManaging the huge influx of patients in hospitals is one of the most critical challenges of the current COVID-19 pandemic. Shimmer’s Bioimpedance Monitor has the potential to help manage this challenge by monitoring HR, respiration rate and depth and the increase in fluid in the lungs to triage and remotely monitor patients. Background Bioimpedance, specifically across the lungs, has long been studied in Chronic Heart Failure (CHF) and Acute Respiratory Distress Syndrome (ARDS). This measurement provides useful indicators of respiration, including rate, volume, and fluid in the lungs. Because COVID-19 attacks the lungs, these measurements provide clear indications of the progression of the disease. This information can be used in many ways, potentially including: • Monitoring patients remotely at home to determine, if and when, they will need to be admitted to the hospital • Monitoring patients in a hospital to determine when they need more aggressive treatment (e.g., ventilators) • Enabling the earlier release of non-acute patients because of the ability to monitor at home • Adjusting the treatment depending on the rate of progression of disease
- 1
- 2
